Dr. Dupont is a renowned expert in the fields of cell therapy and oncology, with long-standing and deep experience in developing therapies and programs dedicated to addressing high unmet medical needs. Dr. Dupont was previously Global Head of Research & Development (R&D) including Medical and Regulatory Affairs at Atara. He also served as the CMO at Gossamer Bio. Prior to Gossamer, he served as VP and Global Head of Breast and Gynecologic Cancer Development for Roche, where he was responsible for the global development of Herceptin®, Perjeta®, Kadcyla®, and Tecentriq®, among others. Prior to that, Dr. Dupont was CMO and SVP of OncoMed. Dr. Dupont has been involved in tumor immunology research and clinical investigations for more than 25 years, ranging from cellular therapy to tumor vaccine therapy and immune checkpoints. Dr. Dupont has received numerous grants and awards, and has co-authored 47 peer-reviewed publications, has 30 patents, and has also served as a faculty member and laboratory researcher at Memorial Sloan Kettering Cancer Center (MSK) and adjunct clinical faculty in medical oncology at Stanford University. Dr. Dupont received his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University, his M.A. in philosophy from NYU.